

Tentative Outline

Special Thematic Issue for Current Pharmaceutical Biotechnology

Liposomes and immunoliposomes as nanocarriers for diagnosis and therapy

Guest Editors: Prof. Mourad Aribi, PhD, Dr. Hab.

Aims & Scope:

Among the major problems of conventional treatments is the inability to reach targets without affecting normal organs and tissues. Therefore, liposomes are one of the most effective for not only limiting such adverse off-target effects, but also for improving drugs pharmacokinetic and biodistribution in appropriate concentrations, while decreasing the risk of systemic toxicity. As spherical-shaped vesicles, their efficiencies and formulations depend on several physicochemical and biological characteristics, such as the nature of their components, their half-life, their size, the number of lamellae, their surface charge, their lipid composition, their surface modification, and their interaction with host cells, etc. They can contain antigens or broad range of drugs, including those for immunological therapeutic purposes designed for both preclinical studies and clinical translation, thus playing the role of successful and ideal immunopharmaceutical nanocarriers for various ailments therapy. The use of liposomes is not limited to drug delivery, but could also be extended to immunodiagnosis based especially on imaging agents and the detection of a given antigen by a specific antibody incorporated onto their surfaces. The purpose of this special issue proposal is to collect new advanced technologies on liposomes and immunoliposomes that are intended for research, diagnosis and clinical application in the therapy of cancer, infectious and autoimmune diseases.

Keywords: Immunoliposome, Immunotherapy, Immunodiagnosis, Drug, Antigen, Vaccine, Cancer, Infectious diseases, and Autoimmune disorders

Subtopics:

The subtopics to be covered within this issue are listed below:

- Liposomes and immunoliposomes technology.
- Multifunctional liposomes and immunoliposomes development.
- Immunoliposomes as nanocarriers for cancer immunotherapy and vaccination.
- Immunoliposomes as nanocarriers for immune regulation and immunotherapy of autoimmune diseases.
- Immunoliposomes as nanocarriers for enhancing immune response against infections.
- Immunoliposomes as nanocarriers for immunodiagnosis.

Schedule:

- Manuscript submission deadline: June 10, 2019
- Peer Review Due: July 24, 2021
- Revision Due: August 12, 2021
- Announcement of acceptance by the Guest Editors: September 6, 2021
- Final manuscripts due: October 1, 2021.

Guest Editor

Affiliation: Laboratory of Applied Molecular Biology and Immunology, BioMolim, W0414100, Imama-Mansourah, Rocade # 2, Department of Biology. University of Tlemcen, 13000 Tlemcen, Algeria. Tel: +213-0-556-281-751. Fax: +213-0-4321-5534. PO Box: 262, Imama-Mansourah, Tlemcen, 13000, Algeria

Email: <m_aribi@mail.univ-tlemcen.dz> or <m_aribi@outlook.fr> or <m_aribi@yahoo.fr>.

Any queries should be addressed to cpb@benthamsience.net